Two people are indicted in Florida over an alleged counterfeit Ozempic smuggling scheme, according to U.S. authorities. CBS and CNBC both report that the case involves two Indian nationals accused of bringing counterfeit versions of the diabetes drug into the United States and distributing them to U.S. buyers at discounted prices.
The reporting frames the prosecution as part of a broader DOJ effort targeting illegal supply chains for GLP-1 weight-loss and diabetes medications. CNBC adds context that demand for GLP-1 drugs such as Ozempic has been rising, including among U.S. adults, which may increase incentives for counterfeiters. CBS focuses on the alleged actions in the Florida distribution channel, while CNBC emphasizes the timing alongside the wider surge in GLP-1 use.
Both outlets describe a criminal indictment tied to the alleged import and sale of counterfeit Ozempic, with the DOJ linking the conduct to shipments originating from outside the U.S.
